Literature DB >> 1592432

The adjuvant activity of non-ionic surfactant vesicles (niosomes) on the BALB/c humoral response to bovine serum albumin.

J M Brewer1, J Alexander.   

Abstract

The ability of non-ionic surfactant vesicles (NISV) to enhance antibody production against bovine serum albumin (BSA) was compared with Freund's complete adjuvant (FCA), in the BALB/c mouse. Two subcutaneous inoculations with NISV entrapped BSA induced antibody levels comparable to, and persisting as long as those produced by FCA by either the subcutaneous or intraperitoneal route of inoculation. Intraperitoneal inoculation of NISV did not generate as strong an antibody response. The adjuvant activity of NISV was wholly dependent on the BSA being entrapped within preformed vesicles; mixing free BSA with vesicles was not effective. Analysis of the anti-BSA IgG subclasses induced by NISV and FCA showed that NISV were generally better stimulators of IgG2a than was FCA, but poorer stimulators of IgG1. From this, we deduce that NISV are potentially better stimulators of the Th1 lymphocyte subset than is FCA and by inference, potent stimulators of cellular immunity. We believe that NISV may offer many advantages over other adjuvants in terms of immunological selectivity, low toxicity and stability.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1592432      PMCID: PMC1384832     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  29 in total

1.  Murine Th1 and Th2 clones proliferate optimally in response to distinct antigen-presenting cell populations.

Authors:  T F Gajewski; M Pinnas; T Wong; F W Fitch
Journal:  J Immunol       Date:  1991-03-15       Impact factor: 5.422

2.  Effect of liposome encapsulation on antigen presentation in vitro. Comparison of presentation by peritoneal macrophages and B cell tumors.

Authors:  P Dal Monte; F C Szoka
Journal:  J Immunol       Date:  1989-03-01       Impact factor: 5.422

3.  The mode of action of mineral-oil emulsion adjuvants on antibody production in mice.

Authors:  W J Herbert
Journal:  Immunology       Date:  1968-03       Impact factor: 7.397

4.  The effect of non-ionic surfactant vesicle (niosome) entrapment on the absorption and distribution of methotrexate in mice.

Authors:  M N Azmin; A T Florence; R M Handjani-Vila; J F Stuart; G Vanlerberghe; J S Whittaker
Journal:  J Pharm Pharmacol       Date:  1985-04       Impact factor: 3.765

5.  Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins.

Authors:  T R Mosmann; H Cherwinski; M W Bond; M A Giedlin; R L Coffman
Journal:  J Immunol       Date:  1986-04-01       Impact factor: 5.422

6.  The distribution of doxorubicin in mice following administration in niosomes.

Authors:  A Rogerson; J Cummings; N Willmott; A T Florence
Journal:  J Pharm Pharmacol       Date:  1988-05       Impact factor: 3.765

7.  Effective immunization against cutaneous leishmaniasis with defined membrane antigens reconstituted into liposomes.

Authors:  D G Russell; J Alexander
Journal:  J Immunol       Date:  1988-02-15       Impact factor: 5.422

8.  Different T helper cell subsets elicited in mice utilizing two different adjuvant vehicles: the role of endogenous interleukin 1 in proliferative responses.

Authors:  J L Grun; P H Maurer
Journal:  Cell Immunol       Date:  1989-06       Impact factor: 4.868

9.  The adjuvant activity of nonionic block polymer surfactants. II. Antibody formation and inflammation related to the structure of triblock and octablock copolymers.

Authors:  R L Hunter; B Bennett
Journal:  J Immunol       Date:  1984-12       Impact factor: 5.422

10.  Differential regulation of IgG1 and IgE synthesis by interleukin 4.

Authors:  C M Snapper; F D Finkelman; W E Paul
Journal:  J Exp Med       Date:  1988-01-01       Impact factor: 14.307

View more
  9 in total

1.  Consideration of the efficacy of non-ionic vesicles in the targeted delivery of oral vaccines.

Authors:  Jitinder S Wilkhu; Sarah E McNeil; David E Anderson; Yvonne Perrie
Journal:  Drug Deliv Transl Res       Date:  2014-06       Impact factor: 4.617

Review 2.  Progress towards a needle-free hepatitis B vaccine.

Authors:  Filipa Lebre; Gerrit Borchard; Maria Conceição Pedroso de Lima; Olga Borges
Journal:  Pharm Res       Date:  2010-11-19       Impact factor: 4.200

3.  Immunization of BALB/c mice with killed Neospora caninum tachyzoite antigen induces a type 2 immune response and exacerbates encephalitis and neurological disease.

Authors:  T V Baszler; T F McElwain; B A Mathison
Journal:  Clin Diagn Lab Immunol       Date:  2000-11

4.  Neither interleukin-6 nor signalling via tumour necrosis factor receptor-1 contribute to the adjuvant activity of Alum and Freund's adjuvant.

Authors:  J M Brewer; M Conacher; M Gaffney; M Douglas; H Bluethmann; J Alexander
Journal:  Immunology       Date:  1998-01       Impact factor: 7.397

5.  The demonstration of an essential role for macrophages in the in vivo generation of IgG2a antibodies.

Authors:  J M Brewer; J Richmond; J Alexander
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

6.  The in vivo production of specific human antibodies by vaccination of human-PBL-SCID mice.

Authors:  W Walker; G Gallagher
Journal:  Immunology       Date:  1994-10       Impact factor: 7.397

7.  Niosome: A future of targeted drug delivery systems.

Authors:  Karim Masud Kazi; Asim Sattwa Mandal; Nikhil Biswas; Arijit Guha; Sugata Chatterjee; Mamata Behera; Ketousetuo Kuotsu
Journal:  J Adv Pharm Technol Res       Date:  2010-10

8.  A niosome formulation modulates the Th1/Th2 bias immune response in mice and also provides protection against anthrax spore challenge.

Authors:  Himanshu Gogoi; Rajesh Mani; Rakesh Bhatnagar
Journal:  Int J Nanomedicine       Date:  2018-11-14

9.  Lawsone-loaded Niosome and its antitumor activity in MCF-7 breast Cancer cell line: a Nano-herbal treatment for Cancer.

Authors:  Mahmood Barani; Mohammad Mirzaei; Masoud Torkzadeh-Mahani; Mohammad Hadi Nematollahi
Journal:  Daru       Date:  2018-07-27       Impact factor: 3.117

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.